ArticleCardio-oncology (London, England)2025
Cardiovascular disease and diagnosis of advanced prostate cancer.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence.International journal of molecular sciences · 2026Pooled it
- American Heart Association cardiovascular health metrics and cancer outcomes: A systematic review and meta-analysis.American heart journal · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionCardiovascular disease (CVD) and cancer are the two leading causes of death in the US. Preclinical models support a direct effect of cardiovascular disease (CVD) on accelerated cancer growth and spread. Our objective is to test the hypothesis that individuals with prevalent CVD are at an increased risk of presenting with more advanced prostate cancer at diagnosis.
methodsWe conducted a case-control study in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases from 2010-2019. The analysis was undertaken from October 2024 to February 2025. We included male individuals aged ≥ 67 years diagnosed with invasive prostate cancer with at least two healthcare interactions and evidence of PSA screening in the 3 to 24 months prior to cancer diagnosis. Our exposure of interest was CVD in the 3 to 24 months prior to cancer diagnosis. Our a priori hypothesis tested the odds of prevalent CVD in patients with localized (T1-2 and N0 and M0) versus advanced (T3-4 or N + or M +) prostate cancer at diagnosis.
resultsOur analysis included 12,120 matched individuals, with median age 75 years (interquartile range 71-80), of which 88% were white, 8% were black, and 59% had prevalent CVD. Multivariable adjusted models demonstrated that individuals with advanced prostate cancer at diagnosis had a statistically significant 10% increased odds of prevalent CVD (OR, 1.10; 95% CI, 1.00-1.22; p = 0.047). This finding was strongest when examining individuals with regional or distant spread at diagnosis (N + or M + ; OR, 1.19; 95% CI, 1.05-1.34; p = 0.006). Further, individuals with Gleason score ≥ 8 disease at diagnosis, had an increased odds of prevalent CVD (OR, 1.07; 95% CI, 1.01-1.13; p = 0.020).
conclusionWe demonstrate an association between prevalent CVD and advanced prostate cancer at diagnosis. Our results may help guide patients regarding personalized screening decisions, given current guidelines recommending shared decision-making, and can be used to facilitate targeted screening approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.